AKBA ▲ +1.8% - Akebia Therapeutics, Inc. $AKBA - U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week 26-OCT-2026 09:20 AM ET